36 results on '"Blaise, Didier"'
Search Results
2. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report
3. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
4. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
5. A Single Center Real World Experience of Allogeneic HSCT of Patients with MDS/CMML in Aged Population
6. Treatment Duration and Complete Response (CR) in Adult and Pediatric Patients (Pts) Treated with Defibrotide (DF) for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT) in the Defifrance and EBMT PASS Registries
7. Trends in Allogeneic Transplantation for Favorable Risk Acute Myeloid Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT
8. Young (<35 years) Haploidentical Versus Old (>35 years) Mismatched Unrelated Donors and Vice Versa for Allogeneic Stem Cell Transplantation with post-Transplant Cyclophosphamide in Patients with Acute Myeloid Leukemia in First Remission: a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
9. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.
10. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas
11. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell–Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia
12. Feasibility of Cyclosporine Prophylaxis Withdrawal in Critically Ill Allogenic Hematopoietic Stem Cell Transplant Patients Admitted to the Intensive Care Unit With No GVHD
13. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
14. Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
15. Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide
16. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
17. Outcomes of Defibrotide-Treated Patients (Pts) with Anicteric/Icteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Results from the Defifrance Registry Study
18. Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients (Pts) with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Pooled Analysis of Defifrance and EBMT PASS Registries
19. An Elite Sport-Inspired Coaching Strategy for Patients after Allogeneic Hematopoietic Stem Cell Transplantation: The Rebond Program
20. Non-T Depleted Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Secondary Versus De Novo AML: A Study from the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
21. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas
22. Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide (DF) for the Treatment of Severe/Very Severe Veno-Occlusive Disease/ Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)
23. Haploidentical Versus Matched Unrelated Donor Transplants for Lymphomas Using Post-Transplant Cyclophosphamide: A Joint CIBMTR/EBMT Study
24. Defibrotide (DF) Treatment in Pediatric (ped) and Adult Patients (pts) with Severe or Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Final Results from the Defifrance Study
25. Young (35 years) Mismatched Unrelated Donors and Vice Versa for Allogeneic Stem Cell Transplantation with post-Transplant Cyclophosphamide in Patients with Acute Myeloid Leukemia in First Remission: a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
26. Non-T-Cell Depleted Haploidentical Stem Cell Transplantation (haploHCT) with Post Transplantation Cyclophosphamide (PTCy)- the Role of Donor Kinship: From the ALWP of the EBMT
27. 487 - An Elite Sport-Inspired Coaching Strategy for Patients after Allogeneic Hematopoietic Stem Cell Transplantation: The Rebond Program
28. 175 - Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients (Pts) with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Pooled Analysis of Defifrance and EBMT PASS Registries
29. 171 - Outcomes of Defibrotide-Treated Patients (Pts) with Anicteric/Icteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Results from the Defifrance Registry Study
30. 29 - Non-T Depleted Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Secondary Versus De Novo AML: A Study from the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
31. 181 - Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide (DF) for the Treatment of Severe/Very Severe Veno-Occlusive Disease/ Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)
32. 89 - Haploidentical Versus Matched Unrelated Donor Transplants for Lymphomas Using Post-Transplant Cyclophosphamide: A Joint CIBMTR/EBMT Study
33. 19 - Defibrotide (DF) Treatment in Pediatric (ped) and Adult Patients (pts) with Severe or Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Final Results from the Defifrance Study
34. 269 - Non-T-Cell Depleted Haploidentical Stem Cell Transplantation (haploHCT) with Post Transplantation Cyclophosphamide (PTCy)- the Role of Donor Kinship: From the ALWP of the EBMT
35. Graft-versus-Host Disease Prophylaxis with Post Transplant Cyclophosphamide in Chronic Myeloid Leukemia patients undergoing Allogeneic Hematopoietic Cell Transplant from either an Unrelated or Mismatched Related Donor: a comparative study from the Chr....
36. Risk Factors for early CMV reactivation and Impact of early CMV reactivation on Clinical Outcomes after T Cell-replete Haploidentical Transplantation with Post-transplant Cyclophosphamide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.